Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.

Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.

Abstract: Several psychotropic compounds are known to influence the sleep-EEG. In very rare cases sleep abnormalities like parasomnia or arousal disorders have additionally been reported during psychotropic drug treatment. We report the case of a 19-year old female patient with a depressive episode and intermittent somnambulism under treatment with reboxetine. The patient with a history of somnambulism in early childhood again suffered from episodes of somnabulism which disappeared after a dose reduction of the drug. In patients having a predisposition for developing parasomnia, a treatment with reboxetine might induce somnambulism.

Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions

Abstract: An overview of drug metabolism, with particular focus on the cytochrome p450 system, is provided in this review. To date, there has been a growing body of literature concerning the cytochrome p450 enzyme, drug-drug interactions and the role of psychotropic medications when co-administered with medications prescribed in the medically ill population. The article provides an ability to cross-reference commonly prescribed medications to their known involvement as substrates, inhibitors or inducers of p450 enzymes. This information will permit the clinician working in an oncologic setting to better predict potential interactions based on available in vitro and in vivo data and choose psychotropics analytically when confronted with a situation of polypharmacy. A knowledge of drug interactions will decrease the uncertainty in prescription of multidrug therapies and minimize the likelihood of diminished drug efficacy or toxic reactions.

The Symptom-Rating Test

Abstract: The Symptom-Rating Test (SRT) was originally designed to measure changes in the symptoms of neurotic adults and in experiments in therapeutics, such as drug trials. After several stages of research, new versions were designed to make the scale more economical and sensitive to discriminate between the effects of psychotropic drugs and placebo, or between two drugs in double-blind drug trials. It has been found to be a measure of distress and it has been used effectively with depressed patients [5, 10,19, 20, 24], in psychosomatic disorders [9-11, 21], in schizophrenics [15, 16], and in epidemiological studies [6, 7].

Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic.

Abstract: Background: The COVID-19 pandemic has caused mental health problems worldwide. The psychopathological implications of COVID-19 in cancer patients have rarely been addressed. Considering the increased vulnerability of oncology patients, this issue needs to be addressed to improve the long-term mental health status of these patients. Methods: We conducted a prospective study in outpatients under active cancer treatment during the first wave of the COVID-19 pandemic. A semi-structured 24-question survey was designed to measure baseline sociodemographic, psychosocial and COVID-19 exposure characteristics. The Hospital Anxiety and Depression Scale was used to measure psychological symptoms. A descriptive and analytical univariate analysis of the variables studied was performed. We used the Z-score to compare different populations (experimental and historical control cohort). Results: 104 patients were included, the majority of which were women (64.4%), were above 65 years of age (57.7%), had either lung and breast cancer (56.7%), had advanced disease (64%) and were undergoing chemotherapy (63.5%). 51% of them expressed greater fear of cancer than of COVID-19 infection or both. In relation to HADS, 52.8% of emotional distress, 42.3% of anxiety and 58.6% of depression rates were detected. The main factors related with higher rates of psychological symptomatology were history of previous psychotropic drug consumption and the adoption of additional infection prevention measures because they considered themselves at risk of severe COVID-19 infection (p = 0.008; p = 0.003 for emotional distress, p = 0.026; p = 0.004 for anxiety, and p = 0.013; p = 0.008 for depression). Tumor type, stage, oncologic treatment or rescheduling of cancer treatments were not related to higher levels of psychological symptomatology. Comparison of our results with another population of similar characteristics was not significant (Z score = -1.88; p = 0.060). Conclusions: We detected high rates of emotional distress during the first wave of the COVID-19 pandemic among cancer patients in active treatment (52.8%). This was higher and clinically relevant than observed in a comparable population (42.5%), although not significant. Cancer itself is the main factor of concern for cancer patients, above and beyond the emotional distress generated by COVID-19 pandemic.

Glycogen accumulation in dendrites of the rabbit pallidum following trifluoperazine administration.

Abstract: Following administration of trifluoperazine (a psychotropic drug of the phenothiazine group), the brains of rabbits were examined by electron microscopy, with special reference to the glycogen changes in the globus pallidus, and were compared with the normal materials. After seven days' intramuscular injections of trifluoperazine (10 mg/kg/day), abundant glycogen granules were accumulated in dendrites of pallidum. Those animals showed extrapyramidal symptoms throughout the period. The administration of the drug might inhibit either neural activity or the glycolytic metabolism in dendrites of the pallidum.